Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab induction and maintenance therapy in Japanese patients with moderate to severe ulcerative colitis
2019-001198-10Phase 3
- Sponsor
- Takeda
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Entyvio with Placebo (2 arms). Primary endpoint: Clinical response at Week 10.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-001198-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001198-10.